Video message explains the multiple benefits of the proposed merger and provides an overview of the substantial market opportunity for the combined company to be named Palisade Bio
Original post:
Leading BioSciences Releases Video Message Highlighting Compelling Investment Thesis of Proposed Merger with Seneca Biopharma, Inc.
SANTA ANA, Calif., April 02, 2021 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, today announced that it has changed its corporate name to NKGen Biotech, Inc., which the Company believes best reflects its mission and strategic focus. The name change is effective immediately.
Read the rest here:
NKMax America Announces Corporate Name Change to NKGen Biotech
VALNEVA
Originally posted here:
Valneva - Déclaration d’actions et de droits de vote – Mars 2021
RESEARCH TRIANGLE PARK, N.C., April 02, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 46,300 shares of G1’s common stock to eight employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Inducement Plan”). The stock options were granted as an inducement material to the new employee’s becoming an employee of G1 in accordance with Nasdaq Listing Rule 5635(c)(4).
View original post here:
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, April 02, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an aggregate of 106,000 ordinary shares of Nabriva Therapeutics as an inducement to two newly-hired employees. These grants included a non-statutory option to purchase 100,000 ordinary shares of Nabriva Therapeutics awarded to Daniel Dolan, Nabriva’s newly appointed Chief Financial Officer. Both awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires’ employment compensation.
See the original post:
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual presentation at the Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) held April 9-11, 2021.
See more here:
ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021
Basking Ridge, NJ, April 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (NYSE American: TMBR) ("Timber” or the "Company"), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that its Annual Meeting of Shareholders will be held at 1:00 pm EDT on Thursday, June 3, 2021 (the “Annual Meeting”). The Company has established April 12, 2021 as the record date for the Annual Meeting.
Read this article:
Timber Pharmaceuticals Sets Record Date for Annual Meeting of Shareholders and Provides Update on Its Annual Filings
Montrouge, France, April 2, 2021DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors
See original here:
DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors
Qelbree (viloxazine extended-release capsules) represents the first novel non-stimulant treatment for ADHD in a decade
See more here:
Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD
MANCHESTER, UK, April 04, 2021 (GLOBE NEWSWIRE) -- As concern around the health risks of alcohol-based sanitiser grows, more hospitals are switching to a safer alternative – HOCL (Hypochlorous Acid), produced by SpectrumX. Hospitals have generally used alcohol-based sanitiser to prevent the spread of disease. But is the end of the line approaching for our go-to disinfectants? With other, better products on the rise, the future of alcohol sanitisers appears more and more sterile. Of course, alcohol-based solutions do their job — they kill pathogens. But they're no longer the safest or most effective option on the market. Commonly-used alcohol sanitisers can damage skin and trigger dermatitis, eczema, and psoriasis — all of which can be a living nightmare for ever-disinfecting medical staff. They’re also toxic, posing a risk to small children who might drink them. Just to add fuel to the fire, they’re flammable too — enough to be identified by the NHS as a fire risk when left in hot cars! With these drawbacks becoming more and more well-known, safer alternatives like HOCL are increasingly sought out by medical institutions and commercial clients. Luckily, SpectrumX – an HOCL provider based in the UK – are aiming to step into the breach, with their unique Spectricept solution. Spectricept is completely safe for human use, yet 300 times more effective than bleach at killing pathogens (including bacteria and viruses – yes, even COVID-19). It’s the only effective formulation of HOCL ever created for use in ‘real world’ conditions — and SpectrumX holds the license for the UK and Europe. After a year on the frontlines against COVID-19, the prospect of switching to a safer, skin-friendly disinfectant has been warmly welcomed by medical staff. Consultant Surgeon Dr Gordon Buchanan vouches for HOCL: “My hands are my most important tool for my job. I believe we should be transitioning away from alcohol-based sanitisers in high-use environments.” Dr Gary Davies, Medical Director at Chelsea & Westminster Hospital (where Spectricept is currently used), agrees: “At the start of the pandemic, hand washing and hand sanitisers suddenly became even more important in the drive of preventing and limiting infection, but I don’t think we necessarily imagined we would be using sanitisers so intensively and for such a long period. Over time we have seen a really significant increase in skin conditions suffered by our staff from high usage of alcohol-based sanitisers. We proactively looked for a safe and effective solution to try to prevent this from happening and have now started utilising an HOCL based product produced by SpectrumX. Feedback from staff members has been overwhelmingly positive."Whilst HOCL has important uses in the current pandemic scenario, it’s future applications have monumental potential effects for post-pandemic life. It’s clear that living in a post-pandemic world means embracing a greater level of sanitation in public spaces, the workplace and beyond. SpectrumX are currently supporting the Medical University Hospital Innsbruck who are leading a Phase 2 clinical trial for nebulised treatment of COVID-19 patients using SPC-069. SPC-069 is a new class of HOCL-based therapy designed to treat viral bacterial and fungal infections in the lung and respiratory tract. With the benefit of successful trial data, several other potential infection treatment possibilities will be investigated. These include: pneumonia, bronchitis, asthma, flu & the common cold. With advancing licenses for the only patent-protectable formulation of HOCL in the world, SpectrumX is set to radically alter the way humans treat infectious disease. SpectrumX is currently raising capital prior to its 2021 listing on the London stock exchange. They intend to become a household name with their array of applications. If you would like to learn more about SpectrumX and how they will revolutionise traditional medicine please click here
Read the rest here:
Concerns about alcohol-based sanitisers are changing the way hospitals invest in protecting their staff